Prognostic significance of αV integrin and VEGF in osteosarcoma after chemotherapy

Onkologie

Volumn 31, Issue 10, 2008, Pages 535-540

  Huang, Yunpeng ^a   Lin, Zhixiong ^a   Zhuang, Jianliang ^a   Chen, Yifeng ^a   Lin, Jianhua ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

V integrins; Chemotherapy; Immunohistochemistry; Osteosarcoma; VEGF

Indexed keywords

CD51 ANTIGEN; CISPLATIN; DOXORUBICIN; IFOSFAMIDE; PARAFFIN; VASCULOTROPIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER RELAPSE; CANCER STAGING; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; OSTEOSARCOMA; PROGNOSIS; PROTEIN EXPRESSION; RANK SUM TEST; TUMOR LOCALIZATION; TUMOR NECROSIS;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; INTEGRIN ALPHAV; MALE; OSTEOSARCOMA; PROGNOSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 53949112697     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151685     Document Type: Article

References (39)

1. Tunn PU, Reichardt P: Chemotherapy for osteosarcoma without high-dose methotrexate: a 12-year follow-up on 53 patients. Onkologie 2007;30:228-32.
2. Blay JY: Chemotherapy for osteosarcoma without high-dose methotrexate: another piece in the puzzle. Onkologie 2007;30:226-7.
3. Felding-Habermann B, Fransvea E, O'Toole TE, Manzuk L, Faha B, Hensler M: Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells. Clin Exp Metastasis 2002;19:427-36.
4. Hynes RO: Integrins: versatility, modulation and signaling in cell adhesion. Cell 1992;69:11-25.
5. Clark EA, Brugge JS: Integrins and signal transduction pathways: the road taken. Science 1995; 268:233-9.
6. Kim M, Carman CV, Springer TA: Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science 2003;301:1720-5.
7. Miyamoto S, Akiyama SK, Yamada KM: Synergistic roles for receptor occupancy and aggregation in integrin transmembrane function. Science 1995;267:883-5.
8. Zutter MM, Sun H, Santoro SA: Altered integrin expression and the malignant phenotype: the contribution of multiple integrated integrin receptors. J Mammary Gland Biol Neoplasia 1998;3:191-200.
9. Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, Hughes PE, Pampori N, Shattil SJ, Saven A, Mueller BM: Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA 2001;98:1853-8.
10. Hullinger TG, McCauley LK, DeJoode ML, Somerman MJ: Effect of bone proteins on human prostate cancer cell lines in vitro. Prostate 1998;36:14-22.
11. Platten M, Wick W, Wild-Bode C, Aulwurm S, Dichgans J, Weller M: Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via up-regulation of alpha(V) beta(3) integrin expression. Biochem Biophys Res Commun 2000;268:607-11.
12. Reinmuth N, Liu W, Ahmad SA, Fan F, Stoeltzing O, Parikh AA, Bucana CD, Gallick GE, Nickols MA, Westlin WF, Ellis LM: Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res 2003;63:2079-87.
13. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
14. Ferrara N, Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851-8.
15. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
16. Hutchings H, Ortega N, Plouet J: Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. FASEB J 2003;17:1520-2.
17. Maeda H, Chung Y, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;77:858-63.
18. Ishigami SI, Arii S, Niwano M, Harada T, Mizumoto M, Mori A, Onodera H, Imamura M: Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998;78:1379-84.
19. Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S: Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Cancer 1997;79:206-13.
20. Duan X, Jia SF, Zhou Z, Langley RR, Bolontrade MF, Kleinerman ES: Association of alphavbeta3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells. Clin Exp Metastasis 2004;21:747-53.
21. Koistinen P, Pulli T, Uitto VJ, Nissinen L, Hyypia T, Heino J: Depletion of alphaV integrins from osteosarcoma cells by intracellular antibody expression induces bone differentiation marker genes and suppresses gelatinase (MMP-2) synthesis. Matrix Biol 1999;18:239-51.
22. Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, Higashino F, Mezawa F, Okada F, Ishii S: Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000;6:572-7.
23. Picci P, Bacci G, Campanacci M, Gasparini M, Pilotti S, Cerasoli S, Bertoni F, Guerra A, Capanna R, Albisinni U, Galletti S, Gherlinzoni F, Calderoni P, Sudanese A, Baldini N, Bernini M, Jaffe N: Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer. 1985;56:1515-21.
24. Hughes DE, Salter DM, Dedhar S, Simpson R: Integrin expression in human bone. J Bone Miner Res1993;8:527-33.
25. Sulzbacher I, Birner P, Trieb K, Lang S, Chott A: Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors. Virchows Arch 2002;441:345-9.
26. Miller KD, Sweeney CJ, Sledge GW: Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19:1195-206.
27. Charity RM, Foukas AF, Deshmukh NS, Grimer RJ: Vascular endothelial growth factor expression in osteosarcoma. Clin Orthop Relat Res 2006;448:193-8.
28. Kaya M, Wada T, Kawaguchi S, Nagoya S, Yamashita T, Abe Y, Hiraga H, Isu K, Shindoh M, Higashino F, Okada F, Tada M, Yamawaki S, Ishii S: Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer 2002;86:864-9.
29. Ueda Y, Yamagishi T, Samata K, Hirayama N, Aozuka Y, Tanaka M, Nakaike S, Saiki I: Antitumor effects of synthetic VEGF-receptor binding antagonist, VGA1155. Anticancer Res 2005;25:3973-7.
30. Belvisi L, Riccioni T, Marcellini M, Vesci L, Chiarucci I, Efrati D, Potenza D, Scolastico C, Manzoni L, Lombardo K, Stasi MA, Orlandi A, Ciucci A, Nico B, Ribatti D, Giannini G, Presta M, Carminati P, Pisano C: Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist. Mol Cancer Ther 2005;4:1670-80.
31. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL: Cilengitide targeting of alpha(v) beta(3) integrin receptor synergize with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenograft. Cancer Res 2002;62:4263-72.
32. Vonlaufen A, Wiedle G, Borisch B, Birrer S, Luder P, Imhof BA: Integrin alpha(v)beta(3) expression in colon carcinoma correlates with survival. Mod Pathol 2001;14:1126-32.
33. Folkman J: Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res 2006;312:594-607.
34. Byzova TV, Goldman CK, Pampori N, Thomas KA, Bett A, Shattil SJ, Plow EF: A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol Cell 2000;6:851-60.
35. Tsou R, Isik FF: Integrin activation is required for VEGF and FGF receptor protein presence on human microvascular endothelial cells. Mol Cell Biochem 2001;224:81-9.
36. Wilkinson-Berka JL, Jones D, Taylor G, Jaworski K, Kelly DJ, Ludbrook SB, Willette RN, Kumar S, Gilbert RE: SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2006;47:1600-5.
37. Matsumoto T, Claesson-Welsh L: VEGF receptor signal transduction. Sci STKE 2001;2001:RE21.
38. Hall H, Hubbell JA: Matrix-bound sixth Ig-like domain of cell adhesion molecule L1 acts as an angiogenic factor by ligating alphavbeta3-integrin and activating VEGF-R2. Microvasc Res 2004;68:169-78.
39. Strieth S, Eichhorn ME, Sutter A, Jonczyk A, Berghaus A, Dellian M: Antiangiogenic combination tumor therapy blocking alpha(v)-integrins and VEGF-receptor-2 increases therapeutic effects in vivo. Int J Cancer 2006;119:423-31.